For biotech companies developing innovative therapies, communication with regulatory authorities can influence key development decisions. Yet limited internal regulatory resources, complex scientific questions and evolving evidence can make these interactions difficult to prepare and manage. This is where experienced biotech regulatory consulting can provide valuable support.

When regulatory questions are poorly framed, scientific positions are not sufficiently supported or different functions communicate inconsistent messages, companies risk receiving feedback that leaves important questions unresolved. For lean biotech teams, this can mean additional regulatory interactions, continued uncertainty and delays in decisions that affect clinical, nonclinical or CMC activities.

A strong regulatory communications partner helps turn translate complex scientific and regulatory issues into clear, well-supported discussions with authorities.By aligning the regulatory objective, supporting evidence and company position before engaging with regulators, biotech companies can make better use of each interaction and obtain feedback that supports the next development decision.

What should biotech companies do before engaging with regulatory authorities?

Before engaging with regulatory authorities, biotech companies should define exactly what they need to achieve from the interaction. The objective may be to clarify a development uncertainty, obtain feedback on a proposed approach, discuss a deviation from established guidance or address questions affecting clinical, nonclinical or CMC development.

The first priority is internal alignment. Regulatory, clinical, nonclinical, CMC and other relevant experts should agree on the issue being presented, the company’s proposed position and the evidence supporting it. Conflicting assumptions or fragmented input can weaken the regulatory message and make it more difficult to obtain actionable feedback.

Timing also matters. Regulatory interactions should be planned around key development decision points, so that authority feedback can inform the programme before major resources are committed.

This is where biotech regulatory consulting can be particularly valuable: bringing an experienced regulatory perspective into the preparation process and helping teams address critical questions before they become costly development obstacles.

Why work with Billev Pharma East for biotech regulatory communications?

Biotech regulatory communication is most effective when the people preparing the interaction understand more than the regulatory procedure itself. They need to understand how the scientific, clinical, CMC and regulatory aspects of the development programme connect — and where regulators are most likely to challenge the company’s position.

Billev Pharma East brings regulatory and scientific expertise together to help biotech companies decide what requires authority input, how to position the issue and how to use the feedback received. This focused approach is central to our biotech regulatory consulting support.

Through our regulatory and scientific communication support, we help biotech teams determine which issues genuinely require regulatory input and where stronger internal preparation may resolve uncertainty before approaching an authority. When an interaction is needed, we help ensure that the company’s position is scientifically substantiated, internally aligned and focused on obtaining feedback that supports the next development decision.

Importantly, our involvement does not have to end with a single meeting. We can maintain continuity across previous discussions, authority feedback and subsequent development decisionsas the programme progresses. This continuity helps biotech companies avoid approaching each regulatory interaction in isolation and supports a more coherent dialogue with authorities over time.

For biotech companies looking for specialist support without fragmenting regulatory work across multiple providers, Billev Pharma East offers access to regulatory and scientific expertise within one multidisciplinary team.

Bring us your next regulatory challenge and let us help you preapre for a focused, productive discussion with the authorities.

How to choose a regulatory communications partner for a biotech company

When considering how to choose a regulatory communications partner for a biotech company, prioritise a partner that can understand the science, challenge the regulatory position and strengthen the interaction with authorities— not simply coordinate the process.

A strong partner should be able to understand the scientific issue behind a regulatory question and determine what the company actually needs from the authority. This includes challenging questions that are too broad, identifying gaps in the supporting rationale and helping distinguish issues that require regulatory input from those that should first be resolved internally.

The ability to connect different scientific perspectives is equally important. Regulatory questions rarely exist in isolation, particularly in biotech development. A clinical question may depend on nonclinical evidence, while a proposed development approach may raise CMC or quality considerations. The partner should be able to recognise these connections and ensure that the position presented to regulators remains coherent.

Companies should also assess how well the partner anticipates potential regulatory challenges. Effective regulatory communication requires anticipating where an authority may challenge an assumption, request additional justification or interpret the available evidence differently. Preparation should therefore challenge and strengthen the company’s position before the interaction takes place.

Finally, look beyond the meeting itself. The right regulatory communications partner should help your team understand what the authority’s feedback means for the decisions that follow.

The best fit is therefore a partner that can connect science, regulatory reasoning and communication — and help translate regulatory feedback into clear next steps for the development programme.

How should biotech companies prepare for a regulatory authority interaction?

Preparing for a regulatory authority interaction requires more than drafting the right questions. Biotech companies need to build a briefing package and regulatory narrative that give the authority a clear understanding of the development context, proposed approach and evidence behind it.

The regulatory narrative should then be tested as a whole. Scientific evidence, development assumptions and proposed next steps need to support the same position. This is particularly important when an interaction involves input from clinical, nonclinical, CMC and regulatory specialists, as inconsistencies between disciplines can weaken an otherwise strong argument.

Biotech companies should also consider what regulators may question rather than preparing only for the discussion they expect. Assumptions that depend on limited data, deviations from established guidance, novel development approaches or areas where evidence remains incomplete deserve particular attention. Identifying these points early gives the team an opportunity to strengthen its rationale and prepare for dirrerent regulatory views.

The written materials should make that reasoning easy to follow. For scientific advice, for example, EMA expects applicants to provide specific scientific questions together with their proposed responses or positions and the information necessary to support the discussion.

Effective preparation therefore goes beyond producing a compliant briefing package. It creates a clear connection between the regulatory question, scientific evidence, company position and development decision — helping the team use the interaction to address the uncertainties that matter most.

What makes a regulatory question effective?

An effective regulatory question is designed to obtain feedback that can inform a specific development decision. For biotech companies, this means moving beyond broad requests for confirmation and clearly defining the issue, the proposed approach and exactly where regulatory input is needed.

The question should be supported by a clear company position. Rather than presenting regulators with an open-ended problem, the biotech team should explain how it proposes to address the issue and provide the scientific rationale behind that approach. This gives the authority a concrete position to assess and can lead to more focused and actionable feedback.

Questions should also be prioritised. An authority interaction is not an opportunity to resolve every uncertainty within a development programme. The strongest questions address issues where regulatory feedback could materially influence study design, evidence generation, CMC planning or another important development decision.

Before finalising a question, biotech teams should therefore ask: What do we need the authority to clarify, and what will we do differently once we have the answer?

That distinction can turn regulatory communication from an information exchange into a tool for development decision-making.

What should biotech companies do with regulatory feedback?

After receiving regulatory feedback, biotech companies should convert the authority’s conclusions into documented actions, responsibilities and implications for the development plan. The team should assess not only what regulators said, but what needs to happen next as a result.The first step is to distinguish between clear regulatory expectations, recommendations, unresolved questions and points that may require further clarification. The team should then evaluate how each relevant outcome affects planned clinical, nonclinical, CMC or other development activities.

Context is particularly important. Regulatory feedback should not be interpreted as an isolated statement. It needs to be considered alongside the questions originally asked, the company position presented to the authority, previous regulatory interactions and any assumptions on which the development plan depends.

The company should also document how significant feedback will be addressed. If the authority challenges an approach or requests additional evidence, the implications may extend beyond a single study or regulatory deliverable. They may affect development priorities, evidence-generation plans, timelines or the strategy for a future interaction.

Where feedback remains unclear, the team should consider the appropriate route for clarification rather than relying soley on internal interpretation. Effective regulatory communication therefore continues after the meeting or written response. The real outcome is not simply receiving regulatory feedback, but understanding what it means for the programme and using it to guide subsequent development decisions.

Choose the right regulatory communications partner for your biotech

The right regulatory communications partner can help your biotech company approach critical authority interactions with stronger questions, clearer scientific positions and a better understanding of what regulatory feedback meand for the development programme.

With Billev Pharma East, biotech regulatory consulting combines multidisciplinary regulatory and scientific expertise with practical support for authority interactions. We help you prepare for the interactions that matter and ensure that the questions, scientific rationale and regulatory strategy support your programme’s next steps.

If you are preparing for an important authority interaction or need expert support to strengthen your regulatory communication, talk to Billev Pharma East about your next regulatory challenge.

Frequently asked questions

Sources: 1 -European Medicines Agency (EMA). Scientific advice and protocol assistance, 2 – European Medicines Agency (EMA). European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance – Rev. 16, 3 – European Medicines Agency (EMA). Requesting scientific advice, protocol assistance and qualification of novel methodologies from EMA, 4 – U.S. Food and Drug Administration (FDA). Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. Final Guidance, August 2026, 5 – U.S. Food and Drug Administration (FDA). Small Business and Industry Assistance: Frequently Asked Questions on the Pre-Investigational New Drug (IND) Meeting.